Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23. The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib.
Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
